A5056591004- Advanced Radiotherapy Techniques
- Lung Cancer Diagnosis and Treatment
- Medical Imaging Techniques and Applications
- Lung Cancer Treatments and Mutations
- Radiomics and Machine Learning in Medical Imaging
- Radiation Therapy and Dosimetry
- Hepatocellular Carcinoma Treatment and Prognosis
- Radiopharmaceutical Chemistry and Applications
- Lung Cancer Research Studies
- Esophageal Cancer Research and Treatment
- Cancer survivorship and care
- Thyroid Disorders and Treatments
- Surgical Simulation and Training
- Radiation Detection and Scintillator Technologies
- Cancer, Hypoxia, and Metabolism
- Nonmelanoma Skin Cancer Studies
- Breast Cancer Treatment Studies
- Prostate Cancer Diagnosis and Treatment
- Anatomy and Medical Technology
- Control Systems and Identification
- Effects of Radiation Exposure
- Head and Neck Cancer Studies
- Radiation Dose and Imaging
- Cancer Genomics and Diagnostics
- Ultrasound and Hyperthermia Applications
Landeskrankenhaus Feldkirch
2019-2022
Paracelsus Medical University
2007-2017
Salzburger Landeskliniken
2000-2014
University of Salzburg
2013
University Clinic of Traumatology
2007-2011
Klinik und Poliklinik für Strahlentherapie und Radioonkologie
2009-2010
Unfallkrankenhaus Salzburg
1999
Sequential chemo-radiotherapies with intensive radiation components deliver promising results in non-resected non-small cell lung cancer (NSCLC). In general, doses are determined by dose constraints for normal tissues, not features relevant tumor control. DART-bid targets directly the required control, correlating to volume a differentiated mode.Radiation primary tumors were aligned along increasing size within 4 groups (<2.5 cm/2.5-4.5 cm/4.5-6.0 cm/>6.0 cm; mean number of three...
One of the primary dose-limiting toxicities during thoracic irradiation is acute esophagitis (AE). The aim this study to investigate dosimetric and clinical predictors for AE grade ≥ 2 in patients treated with accelerated radiotherapy locally advanced non-small cell lung cancer (NSCLC). 66 NSCLC were included present analysis: 4 stage II, 44 IIIA 18 IIIB. All received induction chemotherapy followed by dose differentiated (DART-bid). Depending on size (mean three perpendicular diameters)...
To report acute and late toxicity with long-term follow-up, to describe our experiences pulmonary dose constraints. Between 2002 2009, 150 patients 155 histologically/cytologically proven non-small cell lung cancer (NSCLC; tumor stages II, IIIA, IIIB in 6, 55 39%, respectively) received the following median doses: primary tumors 79.2 Gy (range 72.0–90.0 Gy), lymph node metastases 59.4 (54.0–73.8 nodes electively 45 Gy; fractional doses of 1.8 twice daily (bid). In all, 86% 2 cycles...
Reporting further developments evolved since the first report about this conformal technique.Technical progress focused on optimization of quality assurance (QA) program, especially regarding required work input; and beam arrangements.Besides performing regular QA additional time consuming dosimetric measurements verifications no longer have to be accomplished.'Class solutions' treatment plans for six patients with non-resected non-small cell lung cancer in locally advanced stages are...
In radiation treatment of locally advanced non-small cell lung cancer (LA-NSCLC), 'margins' from internal target volumes to planning in the range 12 23 mm are reported, and avoiding exposure contralateral is common practice. We investigated prospectively an approach with tight margins (7 mm) maximal sparing ipsilateral normal lung. Mature results for first endpoint (pneumonitis) further toxicities reported.Primary tumors were treated by VMAT 73.8-90.0 Gy positive correlation tumor volumes,...